|View printer-friendly version|
|BrainStorm Announces Agreements with Mass. General Hospital and California Pacific Medical Center to Participate in Phase 3 Trial of NurOwn® in ALS|
HACKENSACK, N.J. and PETACH TIKVA,
"It is a privilege to be working with Mass. General once again and to welcome
"Prior studies of NurOwn showed promising biological and clinical effects," said Merit E. Cudkowicz, MD, MSc, Professor of Neurology at Harvard Medical School and Chief of Neurology at Massachusetts General Hospital. "Based on the results of the Phase 2 trial in which we participated, a larger confirmatory trial that incorporates repeat dosing is warranted. I look forward to working with Brainstorm on this pivotal study."
"We are all excited about the potential of stem cells for ALS, but the results to date with NurOwn are especially promising," said Dr.
Dr. Merit Cudkowicz is the Julianne Dorn Professor of Neurology at
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn has been administered to approximately 75 patients with ALS in clinical trials conducted in the United States and Israel. In a randomized, double-blind, placebo-controlled clinical trial conducted in the U. S., a clinically meaningful benefit was demonstrated by higher response to NurOwn compared with placebo. For more information, visit the company's website at www.brainstorm-cell.com.
View original content with multimedia:http://www.prnewswire.com/news-releases/brainstorm-announces-agreements-with-mass-general-hospital-and-california-pacific-medical-center-to-participate-in-phase-3-trial-of-nurown-in-als-300489485.html